Evidence map›Paper›PMID 42305257›Full record

ArticleKidney international reports2026

Randomized Controlled Trial of Individualized Intervention for Frailty Reversal in Older Patients With Nondialysis CKD.

Jing Chang, Yuer Liang, Ye Jiang, Zihe Wang, Zihao Wang, Siyu Xue, Fangrong Zhao, Yazhuo Chi, Xiaomeng Feng, Pingping Sun and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Kidney international reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Jing ChangDepartment of Internal Medicine, Beijing Chao-yang Hospital, Capital Medical University, Beijing, China.
Yuer LiangDepartment of Nephrology, Beijing Chao-yang Hospital, Capital Medical University, Beijing, China.
Ye JiangDepartment of Endocrinology, Beijing Chao-yang Hospital, Capital Medical University, Beijing, China.
Zihe WangDepartment of Internal Medicine, Beijing Chao-yang Hospital, Capital Medical University, Beijing, China.
Zihao WangDepartment of Internal Medicine, Beijing Chao-yang Hospital, Capital Medical University, Beijing, China.
Siyu XueDepartment of Internal Medicine, Beijing Chao-yang Hospital, Capital Medical University, Beijing, China.
Fangrong ZhaoDepartment of Internal Medicine, Beijing Chao-yang Hospital, Capital Medical University, Beijing, China.
Yazhuo ChiDepartment of Internal Medicine, Beijing Chao-yang Hospital, Capital Medical University, Beijing, China.
Xiaomeng FengDepartment of Endocrinology, Beijing Chao-yang Hospital, Capital Medical University, Beijing, China.
Pingping SunDepartment of Internal Medicine, Beijing Chao-yang Hospital, Capital Medical University, Beijing, China.
Qianmei SunDepartment of Nephrology, Beijing Chao-yang Hospital, Capital Medical University, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Frailty is highly prevalent among older adults with chronic kidney disease (CKD), yet evidence for targeted intervention remains limited. We evaluated whether a comprehensive geriatric assessment (CGA)-based individualized intervention could reverse frailty in this population. Methods: In this randomized controlled trial conducted at Beijing Chao-yang Hospital, 242 frail patients with CKD (age ≥ 65, stage 3-5 nondialysis CKD, Fried score ≥ 3; excluding life expectancy < 1 year and communication difficulties) were allocated 1:1 to an intervention group receiving a 12-month individualized, CGA-based multidomain program encompassing tailored nutrition, psychological, and physical-function components or to a control group receiving routine care. The primary outcome was frailty reversion at 12 months (transition from Fried frailty score ≥ 3 to < 3), with secondary outcomes of unplanned hospitalization and all-cause mortality. Results: A total of 242 participants were enrolled (mean age 79.98 ± 7.52 years, 55.8% male, 74% had stage 3 CKD). At 12 months, frailty reversion was significantly higher in the intervention group than in the control group (30.6% vs. 7.4%, Conclusion: CGA-based individualized intervention effectively and safely reversed frailty in older nondialysis patients with CKD, predominantly with stage 3 disease. However, no significant impact on unplanned hospitalization or mortality was observed. These findings may not be generalizable to patients with more advanced CKD.

Indexed as

chronic kidney diseaseelderlyfrailtyindividualized intervention

Identifiers

PMID42305257
PMCPMC13265667

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.